SYDNEY Australia 16 April 2020– Following an oversubscribed initial public offering and the first ASX virtual bell ringing listing, trading of shares in Australian rapid blood test company Atomo Diagnostics Limited (Atomo) will commence on the Australian Securities Exchange (ASX) today under the ticker code...

Atomo Diagnostics announced today that it has entered into a binding supply agreement with French diagnostics company, NG Biotech, SAS (NG Biotech), for the supply of Atomo’s integrated blood test devices to NG Biotech to use for its blood-based rapid test to detect COVID-19. Under the...

SYDNEY Australia, 17 March 2020: Australian rapid blood test company Atomo Diagnostics Limited (ACN 142 925 6840) said today it was working with potential OEM customers to develop rapid self-tests for COVID-19 that could deliver results to patients in as little as 15 minutes, and be...